pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$TNGXTango Therapeutics, Inc.

$TNGX25.65+0.27%
Boston, MA, USupdated 14h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Phase 2: 3
3Phase 2
Phase 2
TNG-260
Cervical Cancer
Phase 2
TNG-456
Bladder Cancer
Phase 2
vopimetostat
Bladder Cancer

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Aug 5, 2026
earnings
$TNGX25.65+0.27%
9d ago
Tango Therapeutics, Inc. earnings
Tango Therapeutics, Inc.
→
view all catalysts →

Active trials

  • phase2Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patientsrecruitingn=183
  • phase2Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumorsrecruitingn=225
  • phase2Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumorsterminatedn=110
  • phase2Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Lossrecruitingn=191
  • phase2Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumorsrecruitingn=126
  • phase2Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumorsterminatedn=7

Insider activity

source: SEC Form 4

open-market buys + sells

  • Apr 15, 26SELLCrystal Adam· President, R&D38,460 sh @ $25.00−$962K↗
  • Apr 1, 26SELLCrystal Adam· President, R&D27,000 sh @ $21.20−$572K↗
  • Mar 25, 26SELLCrystal Adam· President, R&D12,000 sh @ $20.11−$241K↗
  • Mar 5, 26SELLCrystal Adam· President, R&D20,251 sh @ $15.00−$304K↗
  • Feb 25, 26SELLCrystal Adam· President, R&D54,345 sh @ $12.77−$694K↗
routine RSU / option mechanics (6)
  • Apr 15, 26option exerciseCrystal Adam · President, R&D38,460 sh
  • Apr 15, 26option exerciseCrystal Adam · President, R&D38,460 sh
  • Apr 1, 26option exerciseCrystal Adam · President, R&D27,000 sh
  • Apr 1, 26option exerciseCrystal Adam · President, R&D27,000 sh
  • Mar 25, 26option exerciseCrystal Adam · President, R&D12,000 sh
  • Mar 25, 26option exerciseCrystal Adam · President, R&D12,000 sh
🐶 Hiring Signal
26 open roles at Tango Therapeutics, Inc. →

Where Tango Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaOncology 26
departmentClinical 10Biostatistics / Data 4Medical Affairs 3Legal & Compliance 1Quality 1R&D / Discovery 1

News

  • Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug
    Plus news about Parabilis Medicines, RA Capital, Tango Therapeutics, Ideaya Biosciences, Bavarian Nordic and Cartesian Therapeutics 💸 Lilly’s $1B Alzheimer’s deal: The Indianapolis drugmaker will…
    endpoints · 2mo ago
identifiers
ticker
$TNGX
SEC CIK
0001819133
country
US
source
sec_tickers
top tags
NSCLC3Oncology3
mentioned in
1news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed just now
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?